Clinical Trial Update: Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study [Phase 2]

View source ↗

Summary

A Phase II trial evaluating cetuximab in combination with irinotecan as third-line therapy for metastatic colorectal cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)

Snippet

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group | Conditions: Colorectal Cancer Metastatic | Phase 2 | Status: TERMINATED